The clinical study of secondary cytoreductive surgery in the treatment of low grade serous ovarian cancer

Objective: To investigate the therapeutic effect of secondary cytoreductive surgery in the patients with low grade serous ovarian cancer and to analyze the influence of the postoperative quality of life. Method: We collected the clinical data of patients with low grade serous carcinoma who underwent secondary cytoreductive surgery in our hospital from January 2003 to January 2015, and performed a retrospective analysis. We collected the basic data of patients, survival information, chemotherapy and disease related characteristics. We recorded the patient’s postoperative treatment, overall survival (OS), disease-free survival (DFS) and death situation, and evaluated the quality of life of patients before and after the secondary cytoreductive surgery according to European organization for research and treatment of cancer quality of life questionair (EORTC QLQ-C30). Results: A total of 50 patients with low grade ovarian cancer were enrolled in this study. There were 39 patients (78%) with grogs residual disease (GRD) among the 50 patients. The median DFS was 57.4 months and 14.9 months respectively for patients without and with GRD. The median OS was 92.9 months and 70.4 months respectively for patients without and with GRD. The Cox multivariate regression analysis showed that the risks of survival with disease and death in patients with GRD were 3.27 and 2.04 times greater than who without GRD. The results were applied comparative t-test and showed that the postoperative quality of life was better than that preoperative in patients (P<0.05). Conclusion: Whether the secondary cytoreductive surgery is performed thoroughly or not is closely related to the disease-free survival and overall survival of patients with low grade serous ovarian cancer. The implementation of secondary cytoreductive surgery is helpful to improve the quality of life of patients.